PLX
HealthcareProtalix BioTherapeutics, Inc.
$1.79
+$0.05 (+2.87%)
Jan 5, 2026
Price History (1Y)
Analysis
Protalix BioTherapeutics, Inc. is a biotechnology company listed in the Healthcare sector with a market capitalization of $143.95M and revenue of $61.84M (TTM). The company has 213 employees. Financially, Protalix reported gross margins of 57.5%, operating margins of 11.9%, and profit margins of 8.7%. The company's returns on equity and assets are 12.6% and 5.5%, respectively. Its balance sheet shows $29.37M in cash and $8.18M in debt, with a debt-to-equity ratio of 15.46. Protalix's valuation metrics include a P/E ratio (TTM) of 22.38, forward P/E of 2.89, price to book of 2.72, and EV/EBITDA of 15.26. The company has experienced revenue growth of -0.6% and earnings growth of -1.0% on a year-over-year basis.
This analysis is AI-generated for informational purposes only and should not be considered financial advice. Data may be delayed or inaccurate. Always do your own research and consult a qualified financial advisor before making investment decisions.
About Protalix BioTherapeutics, Inc.
Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on the ProCellEx plant cell-based protein expression system. The company offers Elelyso for the treatment of Gaucher disease; and Elfabrio for the treatment of adult patients with a confirmed diagnosis of Fabry disease. It is also developing PRX-115, a plant cell expressed recombinant PEGylated Uricase, which is in Phase 2 trial for the treatment of gout; and PRX-119, a plant cell expressed PEGylated recombinant human DNase I product candidate for the treatment of neutrophil extracellular traps diseases. The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz; and Chiesi Farmaceutici S.p.A. Protalix BioTherapeutics, Inc. has strategic partnership with Secarna Pharmaceuticals GmbH & Co KG. It operates in the United States, Australia, Canada, Israel, Brazil, Russia, and Turkey. The company is headquartered in Hackensack. New Jersey.
Visit website →Key Statistics
- Market Cap
- $143.95M
- P/E Ratio
- 22.38
- 52-Week High
- $3.10
- 52-Week Low
- $1.32
- Avg Volume
- 725.67K
- Beta
- -0.25
Company Info
- Industry
- Biotechnology
- Exchange
- ASE
- Country
- United States
- Employees
- 213